IP Library Granted Patent US 8,999,654
Granted Patent B2
US 8,999,654 · App. 12/916,227 · Granted Apr 7, 2015

Method of identifying a compound for the treatment or prevention of obesity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,654
App. No.
12/916,227
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.

Claims (6)

1. A method for identifying a candidate compound for use in reducing the body weight of a mammalian subject, said method comprising:

(a) contacting a cell expressing a SREB3 polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO. 243 with a candidate compound;

(b) measuring the expression of said SREB3 polypeptide expressed in said cell,

(c) contacting a cell expressing a SREB2 polypeptide comprising an amino acid sequence having at least 95% identity the amino acid sequence set forth in SEQ ID NO. 552 with said candidate compound; and

(d) measuring the expression of said SREB2 polypeptide expressed in said cell,

wherein the candidate compound is identified as a compound for use in reducing the body weight of a mammalian subject when a decrease in the expression of said SREB3 polypeptide is measured in a cell contacted with said compound relative to a cell not contacted with said compound and a decrease in the expression of said SREB2 polypeptide is measured in a cell contacted with said compound, relative to a cell not contacted with said candidate compound.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
SECURITY INTEREST Recorded Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →